CytoTools : announces personnel change

• The CytoTools AG has appointed a new board member for the medical field. The newly structured division, which is also responsible for clinical development and regulatory approval, has been taken over by the experienced pharmaceuticals manager Dr. med. Wilfried Hauke, an internationally renowned expert in clinical development and research.

• The primary goal of his work will be to acquire and analyse the clinical data of a new clinical phase III trial on the efficacy and tolerance of the product DermaPro® in Europe.

Darmstadt, 21st October 2016 - The CytoTools AG, a technology holding with investments in the pharmaceuticals and medical products field, announces a change in the executive board: Dr. Markus Weissbach is leaving the executive board. We are pleased that Dr. med. Wilfried Hauke, a very experienced manager from the pharmaceutical industry at an international level, has agreed to take over the leadership of the fields of medicine, clinical development and regulatory approval. Dr. Hauke previously held responsibility in comparable positions in product development. He has comprehensive knowledge in the conception and execution of large international trials, among others also repeat trials, which can become necessary for various reasons. Over the previous years, Dr. Hauke held the position of CMO (Chief Medical Officer) at Trophos, Marseilles, a biotechnology enterprise which has developed new drugs, e.g. Olesoxime, to treat rare, neurodegenerative diseases. After the first development was unsuccessful, an efficacy study in a comparable indication was completed successfully. Trophos was then taken over by Hoffmann-La Roche in 2015, including all product rights.

With the appointment of Dr. Hauke, the CytoTools AG is concentrating on its main target- starting the repeat of the clinical phase III trial on DermaPro® and bringing this to a successful conclusion in accordance with other results to date.

CEO Dr. Mark-Andre Freyberg summarised: "With Dr. Wilfried Hauke, the CytoTools AG has been successful in winning the services of a top manager from the pharmaceutical industry. The focus of his expertise lies in his experience and knowledge of making a repeat trial a success and completing it with convincing results. We thus reiterate our conviction that we can bring the DermaPro® project to a successful conclusion. We consider, today as yesterday, DermaPro® to be an active substance of enormous potential. We are convinced that Dr. Hauke will realise the coming trials, effectively, efficiently and in the shortest possible time."

This press release contains specific future-oriented statements. These reflect the opinion of CytoTools on the date of this release. The actual results achieved by CytoTools could substantially deviate from the future- oriented statements made. CytoTools is not obligated to update these future-oriented statements.

The CytoTools AG, previously CytoTools GmbH, is a technology investment and holding company which holds shares in its subsidiaries with product development in the pharmaceutical and medical field: about 57 % of the DermaTools Biotech GmbH (therapy fields, dermatology, urology) and 42 % of the CytoPharma GmbH (therapy fields cardiovascular disease, cancer). The complete know-how is protected by corresponding patents which the CytoTools AG upholds worldwide and which it passes on to the subsidiary companies in the form of worldwide exclusive licenses.

CytoTools AG

Dr. Mark Andre Freyberg Klappacher Str. 126

D-64285 Darmstadt

Tel.: +49-6151-95158-12

Fax: +49-6151-95158-13

E-Mail: freyberg@cytotools.de